{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T15:37:22Z","timestamp":1789227442660,"version":"build-2803163510"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI21\/0199"],"award-info":[{"award-number":["PI21\/0199"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["INT23\/00072"],"award-info":[{"award-number":["INT23\/00072"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["BDNS357800"],"award-info":[{"award-number":["BDNS357800"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute kidney injury (AKI) occurs in 30% of patients infused with chimeric antigen receptor (CAR) T-cells. The purpose of this study was to identify risk factors and long-term outcomes after AKI in patients who received CAR T-cell therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medical records of 115 adult patients with R\/R hematological malignancies treated with CD19-targeted CAR T-cells at Vall d'Hebron University Hospital between July 2018 and May 2021. Baseline demographic data including age, gender, ethnicity, body mass index (BMI), and co-morbidities, as well as the type of hematological neoplasia and prior lines of therapy were collected. Laboratory parameters including serum creatinine and whole blood hemoglobin were retrospectively reviewed and values were gathered for days +1, +7, +14, +21, and +28 post-infusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 24\/115 (21%) patients developed AKI related to CAR T-cell therapy; 6\/24 with AKI over chronic kidney disease (CKD). Two patients had AKI in the context of lymphodepleting (LD) chemotherapy and the other 22 after CAR T-cell infusion, starting at day+1 in 3 patients, day+7 in 13 patients, day +14 in 1 patient, day+21 in 2 patients, and day+28 in 3 patients. Renal function was recovered in 19\/24 (79%) patients within the first month after infusion. Male gender, CKD, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS) were associated with AKI. Male gender, CKD, ICANS grade \u22653 and CRS grade \u22652 were identified as independent risk factors for AKI on multivariable analysis. In terms of the most frequent CAR T-cell related complications, CRS was observed in 95 (82%) patients and ICANS in 33 (29%) patients. Steroids were required in 34 (30%) patients and tocilizumab in 37 (32%) patients. Six (5%) patients were admitted to the intensive care unit (1 for septic shock, 4 for CRS grade \u22652 associated to ICANS grade \u22652, and 1 for CRS grade \u22653). A total of 5 (4.4%) patients died in the first 30 days after CAR T-cell infusion for reasons other than disease progression, including 4 cases of infectious complications and 1 of heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results suggest that AKI is a frequent but mild adverse event, with fast recovery in most patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfae027","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T21:23:22Z","timestamp":1708464202000},"source":"Crossref","is-referenced-by-count":24,"title":["Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies"],"prefix":"10.1093","volume":"17","author":[{"given":"Juan","family":"Le\u00f3n-Rom\u00e1n","sequence":"first","affiliation":[{"name":"Nephrology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research, CSUR National Unit of Expertise for Complex Glomerular Diseases of Spain , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Iacoboni","sequence":"additional","affiliation":[{"name":"Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron , Barcelona , Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona , Bellaterra , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3611-4830","authenticated-orcid":false,"given":"Sheila","family":"Bermejo","sequence":"additional","affiliation":[{"name":"N , Barcelona , Spain"},{"name":"ephrology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research, CSUR National Unit of Expertise for Complex Glomerular Diseases of Spain , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Carpio","sequence":"additional","affiliation":[{"name":"Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Bolufer","sequence":"additional","affiliation":[{"name":"N , Barcelona , Spain"},{"name":"ephrology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research, CSUR National Unit of Expertise for Complex Glomerular Diseases of Spain , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Garc\u00eda-Carro","sequence":"additional","affiliation":[{"name":"Nephrology Department, San Carlos Clinical University Hospital , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"S\u00e1nchez-Salinas","sequence":"additional","affiliation":[{"name":"Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Alonso-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Vall d\u00b4Hebron Hospital Universitari, Vall d\u00b4Hebron Barcelona Hospital Campus , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9468-7920","authenticated-orcid":false,"given":"Oriol","family":"Bestard","sequence":"additional","affiliation":[{"name":"N , Barcelona , Spain"},{"name":"ephrology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research, CSUR National Unit of Expertise for Complex Glomerular Diseases of Spain , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Barba","sequence":"additional","affiliation":[{"name":"Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3621-0766","authenticated-orcid":false,"given":"Mar\u00eda Jos\u00e9","family":"Soler","sequence":"additional","affiliation":[{"name":"N , Barcelona , Spain"},{"name":"ephrology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research, CSUR National Unit of Expertise for Complex Glomerular Diseases of Spain , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"2024031815272648800_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"2024031815272648800_bib2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","article-title":"New development in CAR-T cell therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J Hematol Oncol"},{"key":"2024031815272648800_bib3","first-page":"329","article-title":"The T-body approach: redirecting T cells with antibody specificity","volume-title":"Handb Exp Pharmacol","author":"Eshhar","year":"2008"},{"key":"2024031815272648800_bib4","doi-asserted-by":"crossref","first-page":"djv439","DOI":"10.1093\/jnci\/djv439","article-title":"Chimeric antigen receptors modified T-cells for ancer therapy","volume":"108","author":"Dai","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2024031815272648800_bib5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jgm.2604","article-title":"Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions","volume":"14","author":"Curran","year":"2012","journal-title":"J Gene Med"},{"key":"2024031815272648800_bib6","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"2024031815272648800_bib7","doi-asserted-by":"crossref","first-page":"796","DOI":"10.2215\/CJN.12871117","article-title":"Chimeric antigen receptor T cell therapy and the kidney","volume":"13","author":"Jhaveri","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024031815272648800_bib8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"2024031815272648800_bib9","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"2024031815272648800_bib10","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"2024031815272648800_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2024031815272648800_bib12","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"2024031815272648800_bib13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"2024031815272648800_bib14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"2024031815272648800_bib15","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"2024031815272648800_bib16","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"key":"2024031815272648800_bib17","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"2024031815272648800_bib18","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"2024031815272648800_bib19","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"2024031815272648800_bib20","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3389\/fimmu.2019.01613","article-title":"Chimeric antigen receptor-modified T cell therapy in multiple myeloma: beyond B cell maturation antigen","volume":"10","author":"Timmers","year":"2019","journal-title":"Front Immunol"},{"key":"2024031815272648800_bib21","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int J Biol Sci"},{"key":"2024031815272648800_bib22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"2024031815272648800_bib23","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"2024031815272648800_bib24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jtct.2020.10.002","article-title":"Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies","volume":"27","author":"Chakraborty","year":"2020","journal-title":"Transplant Cell Ther"},{"key":"2024031815272648800_bib25","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"2024031815272648800_bib26","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"2024031815272648800_bib27","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"key":"2024031815272648800_bib28","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"2024031815272648800_bib29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00262-014-1641-9","article-title":"Overcoming the toxicity hurdles of genetically targeted T cells","volume":"64","author":"Casucci","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"2024031815272648800_bib30","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1182\/bloodadvances.2019001304","article-title":"Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial","volume":"4","author":"Schuster","year":"2020","journal-title":"Blood Advances"},{"key":"2024031815272648800_bib31","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024031815272648800_bib32","doi-asserted-by":"crossref","first-page":"796","DOI":"10.2215\/CJN.12871117","article-title":"Chimeric antigen receptor T cell therapy and the kidney what the nephrologist needs to know","volume":"13","author":"Jhaveri","year":"2018","journal-title":"Rosner Clin J Am Soc Nephrol"},{"key":"2024031815272648800_bib33","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","article-title":"Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery","volume":"26","author":"Gutgarts","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024031815272648800_bib34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2024031815272648800_bib35","article-title":"KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"Kellum","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2024031815272648800_bib36","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024031815272648800_bib37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2018.09.024","article-title":"American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistic, and Toxicity Management Practices in the United States","volume":"25","author":"Mahmoudjafari","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024031815272648800_bib38","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/s41409-022-01767-7","article-title":"Comparison of short- and long-term adverse kidney outcomes after chimeric antigen receptor T cell therapy and autologous hematopoietic stem cell transplant for diffuse large B cell lymphoma","volume":"57","author":"Hanna","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"2024031815272648800_bib39","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.clml.2022.07.007","article-title":"Impact of chronic kidney disease and acute kidney injury on safety and outcomes of CAR T-cell therapy in lymphoma patients","volume":"22","author":"Ahmed","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2024031815272648800_bib40","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.mayocp.2022.05.018","article-title":"Incidence and risk factors for acute kidney injury after chimeric antigen receptor T-cell therapy","volume":"97","author":"Farooqui","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"2024031815272648800_bib41","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: A position statement from the Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int"},{"key":"2024031815272648800_bib42","first-page":"972","volume-title":"American Hospital Formulary Service\u2014Drug Information","author":"McEvoy","year":"2001"},{"key":"2024031815272648800_bib43","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1081\/CNV-120005903","article-title":"The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study","volume":"20","author":"Lichtman","year":"2002","journal-title":"Cancer Invest"},{"key":"2024031815272648800_bib44","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.bbmt.2014.02.013","article-title":"Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic kidney disease: analysis of the literature and recommendations","volume":"20","author":"Bodge","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024031815272648800_bib45","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4614-5800-5","volume-title":"Renal pharma- cotherapy: dosage adjustment of medications eliminated by the kidneys","author":"Golightly","year":"2013"},{"key":"2024031815272648800_bib46","first-page":"155","article-title":"Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children","volume-title":"Am J Kidney Dis","author":"Aronoff","year":"1983"},{"key":"2024031815272648800_bib47","first-page":"829","article-title":"Outcomes of CD19-targeted chimeric antigen receptor T cell therapy for patients with reduced renal function including dialysis","volume":"28","author":"Wood","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2024031815272648800_bib48","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s44228-023-00037-7","article-title":"Safety of CAR-T cell therapy in patients with renal failure\/acute kidney injury: focused review","volume":"5","author":"Khan","year":"2023","journal-title":"Clin Hematol Int"},{"key":"2024031815272648800_bib49","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2023","journal-title":"Haematologica"},{"key":"2024031815272648800_bib50","first-page":"137","article-title":"Risk factors of acute kidney injury during BCMA CAR-T cell therapy in patients with relapsed\/refractory multiple myeloma","volume":"51","author":"Lyu","year":"2022","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"2024031815272648800_bib51","author":"US Departament of Health and Human Services"},{"key":"2024031815272648800_bib52","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.ekir.2021.02.013","article-title":"Systematic review of risk factors and incidence of acute kidney injury among patients treated with CAR-T cell therapies","volume":"6","author":"Kanduri","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2024031815272648800_bib53","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrneph.2017.2","article-title":"Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup","volume":"13","author":"Chawla","year":"2017","journal-title":"Nat Rev Nephrol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae027\/56723157\/sfae027.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/3\/sfae027\/57006032\/sfae027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/3\/sfae027\/57006032\/sfae027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T15:55:32Z","timestamp":1710777332000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae027\/7611699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae027","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2024,2,20]]},"article-number":"sfae027"}}